Literature DB >> 11061619

Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma.

D A Anthoney1, I Bone, T R Evans.   

Abstract

Paraneoplastic syndromes (PNS) involving the central nervous system are a rare manifestation of malignant disease. As they commonly precede the diagnosis of malignancy their acute manifestations do not often present themselves to oncologists in the first instance. It is currently believed that most, if not all, neurological PNS are autoimmune in nature. Proteins expressed ectopically on the surface of tumour cells generate an immune response which cross-reacts with the same, or similar, proteins in the nervous system resulting in damage. This can involve a single cell type of the nervous system whilst in other cases the impairment is more widespread. The following report is of a case of chronic inflammatory demyelinating polyneuropathy (CIDP) occurring in metastatic malignant melanoma, following treatment with interferon-alpha. We review the current literature on this rare association and speculate on its pathogenesis, and the implications for future therapeutic strategies in melanoma targeting tumour antigens.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061619     DOI: 10.1023/a:1008362714023

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  9 in total

1.  Chronic inflammatory polyneuropathy revealing malignant melanoma.

Authors:  A Rousseau; F Salachas; M Baccard; J Y Delattre; M Sanson
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

2.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

3.  Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.

Authors:  Bing Liao; Sheetal Shroff; Carlos Kamiya-Matsuoka; Sudhakar Tummala
Journal:  Neuro Oncol       Date:  2014-01-30       Impact factor: 12.300

4.  Chronic inflammatory demyelinating polyneuropathy associated with metastatic malignant melanoma of unknown primary origin.

Authors:  José-Alberto Palma; Salvador Martín-Algarra
Journal:  J Neurooncol       Date:  2009-03-06       Impact factor: 4.130

5.  Limbic encephalitis following immunotherapy against metastatic malignant melanoma.

Authors:  Sharfaraz Salam; Timothy Lavin; Ayse Turan
Journal:  BMJ Case Rep       Date:  2016-03-23

6.  Simvastatin impairs murine melanoma growth.

Authors:  Giovani M Favero; Michel F Otuki; Karen A Oliveira; Milton S Bohatch; Primavera Borelli; Francisco E Barros; Durvanei A Maria; Daniel Fernandes; Sergio P Bydlowski
Journal:  Lipids Health Dis       Date:  2010-12-16       Impact factor: 3.876

Review 7.  Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.

Authors:  Richard J Bright; Jenny Wilkinson; Brendon J Coventry
Journal:  BMC Neurol       Date:  2014-02-07       Impact factor: 2.474

8.  Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.

Authors:  Jocelyn Joseph; Michael J Nathenson; Van Anh Trinh; Karan Malik; Erica Nowell; Kristen Carter; Shiao-Pei Weathers; George D Demetri; Dejka Araujo; Anthony P Conley
Journal:  J Immunother Cancer       Date:  2019-11-08       Impact factor: 13.751

9.  Deregulated Fcγ receptor expression in patients with CIDP.

Authors:  Isaak Quast; Flavio Cueni; Falk Nimmerjahn; Björn Tackenberg; Jan D Lünemann
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-08-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.